You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCelecoxib
Accession NumberDB00482  (APRD00373)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionCelecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.
Structure
Thumb
Synonyms
Celebrex
Celecoxib
Célécoxib
Celecoxibum
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
External Identifiers
  • SC 58635
  • YM 177
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-celecoxibcapsule100 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-celecoxibcapsule200 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Act Celecoxibcapsule100 mgoralActavis Pharma Company2014-11-21Not applicableCanada
Act Celecoxibcapsule200 mgoralActavis Pharma Company2014-11-21Not applicableCanada
Ag-celecoxibcapsule100 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-celecoxibcapsule200 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-celecoxibcapsule200 mgoralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-celecoxibcapsule100 mgoralAuro Pharma Inc2015-12-02Not applicableCanada
Bio-celecoxibcapsule100 mgoralBiomed Pharma2014-12-05Not applicableCanada
Bio-celecoxibcapsule200 mgoralBiomed Pharma2014-12-05Not applicableCanada
Celebrexcapsule100 mg/1oralPhysicians Total Care, Inc.1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralProficient Rx LP1998-10-02Not applicableUs
Celebrexcapsule50 mg/1oralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralH.J. Harkins Company, Inc.1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralSTAT Rx USA LLC1998-10-02Not applicableUs
Celebrexcapsule100 mgoralPfizer Canada Inc1999-04-19Not applicableCanada
Celebrexcapsule100 mg/1oralPd Rx Pharmaceuticals, Inc.1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralAidarex Pharmaceuticals LLC1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralKeltman Pharmaceuticals Inc.2006-03-01Not applicableUs
Celebrexcapsule100 mg/1oralA S Medication Solutions Llc1999-01-25Not applicableUs
Celebrexcapsule100 mg/1oralCardinal Health1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralbryant ranch prepack1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralH.J. Harkins Company, Inc.1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralSTAT Rx USA LLC1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-22Not applicableUs
Celebrexcapsule200 mgoralPfizer Canada Inc1999-04-19Not applicableCanada
Celebrexcapsule200 mg/1oralPd Rx Pharmaceuticals, Inc.1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralDIRECT RX2014-01-01Not applicableUs
Celebrexcapsule200 mg/1oralSTAT Rx USA LLC1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Celebrexcapsule200 mg/1oralA S Medication Solutions Llc1999-01-25Not applicableUs
Celebrexcapsule200 mg/1oralCardinal Health1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralbryant ranch prepack1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralRebel Distributors Corp.1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralClinical Solutions Wholesale1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralDispensing Solutions, Inc.1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralUnit Dose Services1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralPhysicians Total Care, Inc.1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralSTAT Rx USA LLC1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralCardinal Health1998-10-02Not applicableUs
Celebrexcapsule400 mg/1oralbryant ranch prepack1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralREMEDYREPACK INC.2013-02-20Not applicableUs
Celebrexcapsule400 mg/1oralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralRebel Distributors Corp.1998-10-02Not applicableUs
Celebrexcapsule200 mg/1oralAphena Pharma Solutions Tennessee, Llc1998-10-02Not applicableUs
Celebrexcapsule100 mg/1oralUnit Dose Services1998-10-02Not applicableUs
Celecoxibcapsule400 mg/1oralMylan Pharmaceuticals Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mgoralSivem Pharmaceuticals Ulc2014-11-17Not applicableCanada
Celecoxibcapsule200 mg/1oralPd Rx Pharmaceuticals, Inc.2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralBlenheim Pharmacal, Inc.2016-02-12Not applicableUs
Celecoxibcapsule200 mg/1oralPreferred Pharmaceuticals, Inc.2014-12-22Not applicableUs
Celecoxibcapsule50 mg/1oralLupin Pharmaceuticals, Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mgoralPro Doc Limitee2014-11-21Not applicableCanada
Celecoxibcapsule100 mg/1oralGreenstone LLC2014-12-10Not applicableUs
Celecoxibcapsule100 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Celecoxibcapsule400 mg/1oralActavis Pharma, Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Celecoxibcapsule200 mg/1oralbryant ranch prepack2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Celecoxibcapsule50 mg/1oralMylan Pharmaceuticals Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralPreferred Pharmaceuticals, Inc.2014-12-22Not applicableUs
Celecoxibcapsule50 mg/1oralActavis Pharma, Inc.2014-12-10Not applicableUs
Celecoxibcapsule200 mgoralSivem Pharmaceuticals Ulc2014-11-17Not applicableCanada
Celecoxibcapsule100 mg/1oralPd Rx Pharmaceuticals, Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralLupin Pharmaceuticals, Inc.2014-12-10Not applicableUs
Celecoxibcapsule200 mgoralPro Doc Limitee2014-11-21Not applicableCanada
Celecoxibcapsule200 mg/1oralGreenstone LLC2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralbryant ranch prepack2014-12-10Not applicableUs
Celecoxibcapsule200 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Celecoxibcapsule200 mg/1oralUnit Dose Services2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralBlenheim Pharmacal, Inc.2015-05-19Not applicableUs
Celecoxibcapsule200 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Celecoxibcapsule100 mg/1oralMylan Pharmaceuticals Inc.2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-20Not applicableUs
Celecoxibcapsule100 mg/1oralActavis Pharma, Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mgoralSanis Health Inc2015-02-05Not applicableCanada
Celecoxibcapsule200 mg/1oralMedsource Pharmaceuticals2014-12-10Not applicableUs
Celecoxibcapsule100 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Celecoxibcapsule200 mg/1oralLupin Pharmaceuticals, Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralAidarex Pharmaceuticals LLC2014-12-10Not applicableUs
Celecoxibcapsule400 mg/1oralGreenstone LLC2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralUnit Dose Services2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralBlenheim Pharmcal, Inc2015-05-27Not applicableUs
Celecoxibcapsule200 mg/1oralDIRECT RX2015-01-01Not applicableUs
Celecoxibcapsule200 mg/1oralAvera Mc Kennan Hospital2015-05-01Not applicableUs
Celecoxibcapsule100 mg/1oralPreferred Pharmaceuticals Inc.2015-10-06Not applicableUs
Celecoxibcapsule200 mg/1oralMylan Pharmaceuticals Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralAvera Mc Kennan Hospital2015-10-02Not applicableUs
Celecoxibcapsule200 mg/1oralActavis Pharma, Inc.2014-12-10Not applicableUs
Celecoxibcapsule200 mgoralSanis Health Inc2015-02-05Not applicableCanada
Celecoxibcapsule200 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Celecoxibcapsule400 mg/1oralLupin Pharmaceuticals, Inc.2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralAidarex Pharmaceuticals LLC2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralREMEDYREPACK INC.2015-02-25Not applicableUs
Celecoxibcapsule200 mg/1oralBlenheim Pharmacal, Inc.2015-07-20Not applicableUs
Celecoxibcapsule50 mg/1oralGreenstone LLC2014-12-10Not applicableUs
Dom-celecoxibcapsule100 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-celecoxibcapsule200 mgoralDominion PharmacalNot applicableNot applicableCanada
Gd-celecoxibcapsule100 mgoralGenmed A Division Of Pfizer Canada Inc2014-11-20Not applicableCanada
Gd-celecoxibcapsule200 mgoralGenmed A Division Of Pfizer Canada Inc2014-11-20Not applicableCanada
Ipg-celecoxibcapsule200 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-celecoxibcapsule100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-celecoxibcapsule100 mgoralJamp Pharma Corporation2014-11-27Not applicableCanada
Jamp-celecoxibcapsule200 mgoralJamp Pharma Corporation2014-11-27Not applicableCanada
Lupin-celecoxibcapsule100 mgoralLupin Pharma Canada LimitedNot applicableNot applicableCanada
Lupin-celecoxibcapsule200 mgoralLupin Pharma Canada LimitedNot applicableNot applicableCanada
Mar-celecoxibcapsule200 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-celecoxibcapsule100 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mint-celecoxibcapsule100 mgoralMint Pharmaceuticals Inc2014-11-17Not applicableCanada
Mint-celecoxibcapsule200 mgoralMint Pharmaceuticals Inc2014-11-17Not applicableCanada
Mylan-celecoxibcapsule200 mgoralMylan Pharmaceuticals Ulc2014-11-17Not applicableCanada
Mylan-celecoxibcapsule100 mgoralMylan Pharmaceuticals Ulc2014-11-17Not applicableCanada
PMS-celecoxibcapsule100 mgoralPharmascience Inc2014-11-17Not applicableCanada
PMS-celecoxibcapsule200 mgoralPharmascience Inc2014-11-17Not applicableCanada
Priva-celecoxibcapsule200 mgoralPharmapar Inc2014-12-31Not applicableCanada
Priva-celecoxibcapsule100 mgoralPharmapar Inc2014-12-31Not applicableCanada
Ran-celecoxibcapsule200 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-11-17Not applicableCanada
Ran-celecoxibcapsule100 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-11-17Not applicableCanada
Rbx-celecoxibcapsule100 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-celecoxibcapsule200 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Riva-celecoxcapsule100 mgoralLaboratoire Riva Inc2014-11-17Not applicableCanada
Riva-celecoxcapsule200 mgoralLaboratoire Riva Inc2014-11-17Not applicableCanada
Riva-celecoxibcapsule200 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-celecoxibcapsule100 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz Celecoxibcapsule100 mgoralSandoz Canada Incorporated2014-11-17Not applicableCanada
Sandoz Celecoxibcapsule200 mgoralSandoz Canada Incorporated2014-11-17Not applicableCanada
Sdz Celecoxibcapsule100 mgoralSandoz Canada Incorporated2016-05-15Not applicableCanada
Sdz Celecoxibcapsule200 mgoralSandoz Canada Incorporated2016-05-15Not applicableCanada
Teva-celecoxibcapsule100 mgoralTeva Canada Limited2014-11-17Not applicableCanada
Teva-celecoxibcapsule200 mgoralTeva Canada Limited2014-11-17Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-celecoxibcapsule200 mgoralApotex Inc2014-11-17Not applicableCanada
Apo-celecoxibcapsule100 mgoralApotex Inc2014-11-17Not applicableCanada
Celecoxibcapsule400 mg/1oralMylan Pharmaceuticals Inc.2015-04-15Not applicableUs
Celecoxibcapsule200 mg/1oralProficient Rx LP2015-06-03Not applicableUs
Celecoxibcapsule50 mg/1oralAv Kare, Inc.2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralProficient Rx LP2015-03-12Not applicableUs
Celecoxibcapsule200 mg/1oralAurobindo Pharma Limited2016-02-01Not applicableUs
Celecoxibcapsule100 mg/1oralTeva Pharmaceuticals USA Inc2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralApotex Corp.2015-06-03Not applicableUs
Celecoxibcapsule200 mg/1oralPreferred Pharmaceuticals Inc.2016-01-042016-01-07Us
Celecoxibcapsule400 mg/1oralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
Celecoxibcapsule400 mg/1oralActavis Pharma, Inc.2015-03-12Not applicableUs
Celecoxibcapsule100 mg/1oralLupin Pharmaceuticals, Inc.2015-08-07Not applicableUs
Celecoxibcapsule400 mg/1oralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
Celecoxibcapsule100 mg/1oralMylan Institutional Inc.2015-02-24Not applicableUs
Celecoxibcapsule100 mg/1oralTrigen Laboratories, LLC2015-08-22Not applicableUs
Celecoxibcapsule200 mg/1oralCipla USA Inc.2015-09-23Not applicableUs
Celecoxibcapsule200 mg/1oralMylan Pharmaceuticals Inc.2015-04-15Not applicableUs
Celecoxibcapsule200 mg/1oralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
Celecoxibcapsule200 mg/1oralDIRECT RX2016-03-02Not applicableUs
Celecoxibcapsule50 mg/1oralActavis Pharma, Inc.2015-03-12Not applicableUs
Celecoxibcapsule100 mg/1oralAmerican Health Packaging2015-02-20Not applicableUs
Celecoxibcapsule50 mg/1oralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
Celecoxibcapsule100 mg/1oralAv Kare, Inc.2014-12-10Not applicableUs
Celecoxibcapsule400 mg/1oralAurobindo Pharma Limited2016-02-01Not applicableUs
Celecoxibcapsule200 mg/1oralTeva Pharmaceuticals USA Inc2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralSt. Mary's Medical Park Pharmacy2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
Celecoxibcapsule200 mg/1oralMylan Institutional Inc.2015-02-24Not applicableUs
Celecoxibcapsule100 mg/1oralMajor Pharmaceuticals2015-06-25Not applicableUs
Celecoxibcapsule200 mg/1oralLupin Pharmaceuticals, Inc.2015-08-07Not applicableUs
Celecoxibcapsule200 mg/1oralTrigen Laboratories, LLC2015-08-22Not applicableUs
Celecoxibcapsule100 mg/1oralCipla USA Inc.2015-09-23Not applicableUs
Celecoxibcapsule100 mg/1oralMylan Pharmaceuticals Inc.2015-04-15Not applicableUs
Celecoxibcapsule400 mg/1oralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
Celecoxibcapsule200 mg/1oralRx Change Co.2015-06-03Not applicableUs
Celecoxibcapsule100 mg/1oralActavis Pharma, Inc.2015-03-12Not applicableUs
Celecoxibcapsule200 mg/1oralAmerican Health Packaging2015-02-20Not applicableUs
Celecoxibcapsule100 mg/1oralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
Celecoxibcapsule200 mg/1oralAv Kare, Inc.2014-12-10Not applicableUs
Celecoxibcapsule200 mg/1oralPd Rx Pharmaceuticals, Inc.2014-12-10Not applicableUs
Celecoxibcapsule400 mg/1oralTeva Pharmaceuticals USA Inc2014-12-10Not applicableUs
Celecoxibcapsule50 mg/1oralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
Celecoxibcapsule200 mg/1oralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
Celecoxibcapsule400 mg/1oralLupin Pharmaceuticals, Inc.2015-08-07Not applicableUs
Celecoxibcapsule50 mg/1oralAurobindo Pharma Limited2016-02-01Not applicableUs
Celecoxibcapsule50 mg/1oralApotex Corp.2015-06-03Not applicableUs
Celecoxibcapsule200 mg/1oralMajor Pharmaceuticals2015-06-25Not applicableUs
Celecoxibcapsule100 mg/1oralProficient Rx LP2014-12-10Not applicableUs
Celecoxibcapsule400 mg/1oralTrigen Laboratories, LLC2015-08-22Not applicableUs
Celecoxibcapsule50 mg/1oralCipla USA Inc.2015-09-23Not applicableUs
Celecoxibcapsule50 mg/1oralMylan Pharmaceuticals Inc.2015-04-15Not applicableUs
Celecoxibcapsule200 mg/1oralBlenheim Pharmacal, Inc.2015-11-05Not applicableUs
Celecoxibcapsule200 mg/1oralActavis Pharma, Inc.2015-03-12Not applicableUs
Celecoxibcapsule50 mg/1oralLupin Pharmaceuticals, Inc.2015-08-07Not applicableUs
Celecoxibcapsule200 mg/1oralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
Celecoxibcapsule400 mg/1oralAv Kare, Inc.2014-12-10Not applicableUs
Celecoxibcapsule400 mg/1oralCipla USA Inc.2015-09-23Not applicableUs
Celecoxibcapsule50 mg/1oralTeva Pharmaceuticals USA Inc2014-12-10Not applicableUs
Celecoxibcapsule100 mg/1oralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
Celecoxibcapsule50 mg/1oralTrigen Laboratories, LLC2015-08-22Not applicableUs
Celecoxibcapsule50 mg/1oralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
Celecoxibcapsule200 mg/1oralPreferred Pharmaceuticals Inc.2015-10-15Not applicableUs
Celecoxibcapsule100 mg/1oralAurobindo Pharma Limited2016-02-01Not applicableUs
Celecoxibcapsule100 mg/1oralApotex Corp.2015-06-03Not applicableUs
Celecoxib 100 mgcapsule100 mg/1oralSydon Labs Llc2015-11-24Not applicableUs
Celecoxib 200 mgcapsule200 mg/1oralProficient Rx LP2015-11-24Not applicableUs
Celecoxib 200 mgcapsule200 mg/1oralPreferred Pharmaceuticals Inc.2016-01-08Not applicableUs
Celecoxib 200 mgcapsule200 mg/1oralSydon Labs Llc2015-11-24Not applicableUs
Celecoxib 400 mgcapsule400 mg/1oralSydon Labs Llc2015-11-24Not applicableUs
Celecoxib 50 mgcapsule50 mg/1oralSydon Labs Llc2015-11-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OnsenalHard capsules200 mgOral usePfizer Limited2003-10-17Not applicableEu
OnsenalHard capsules400 mgOral usePfizer Limited2003-10-17Not applicableEu
OnsenalHard capsules200 mgOral usePfizer Limited2003-10-17Not applicableEu
OnsenalHard capsules400 mgOral usePfizer Limited2003-10-17Not applicableEu
OnsenalHard capsules200 mgOral usePfizer Limited2003-10-17Not applicableEu
OnsenalHard capsules200 mgOral usePfizer Limited2003-10-17Not applicableEu
International Brands
NameCompany
ArticoxKeyfarm
ArticoxibNabiqasim
ArtiflexStandpharm
ArtilogPfizer
ArtixPharmalab
ArtrixibIntipharma
BlocktenInfarmasa
CaditarFarmindustria
CefinixFarmacoop
CelactSun
CelebraPfizer
OnsenalPfizer
ValdynePfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIJCX84Q7J1L
CAS number169590-42-5
WeightAverage: 381.372
Monoisotopic: 381.075882012
Chemical FormulaC17H14F3N3O2S
InChI KeyInChIKey=RZEKVGVHFLEQIL-UHFFFAOYSA-N
InChI
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
IUPAC Name
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
SMILES
CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassPyrazoles
Direct ParentPhenylpyrazoles
Alternative Parents
Substituents
  • Phenylpyrazole
  • Benzenesulfonamide
  • Toluene
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis
PharmacodynamicsCelecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Celecoxib is used to treat rheumatoid arthritis, osteoarthritis, and familial adenomatous polyposis (FAP). Because of its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis. It is not known if there are any effects of celecoxib on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of celecoxib. Inhibition of PGE2 synthesis may lead to sodium and water retention through increased fluid reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit water reabsorption by counteracting the action of antidiuretic hormone.
Mechanism of actionThe mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis. Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. It binds with its polar sulfonamide side chain to a hydrophilic side pocket region close to the active COX-2 binding site. Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane.
Related Articles
AbsorptionWell absorbed in the gastrointestinal tract. When a single dose of 200 mg is given to healthy subjects, peak plasma levels occur 3 hours after an oral dose. The peak plasma level is 705 ng/mL. Absolute bioavailability studies have not been conducted. When multiple doses are given, steady-state is reached on or before Day 5. When taken with a high fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%.
Volume of distribution

Apparent volume of distribution at steady state (Vdss/F), 200 mg single dose, healthy subjects = 429 L

Protein binding97%, primarily to albumin and, to a lesser extent, a1-acid glycoprotein. Celecoxib is not preferentially bound to red blood cells.
Metabolism

Hepatic. Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. CYP3A4 is also involved in the hydroxylation of celecoxib but to a lesser extent. These metabolites are inactive as COX-1 or COX-2 inhibitors.

SubstrateEnzymesProduct
Celecoxib
HydroxycelecoxibDetails
Hydroxycelecoxib
CarboxycelecoxibDetails
Carboxycelecoxib
Celecoxib glucuronideDetails
Route of eliminationCelecoxib is eliminated predominantly by hepatic metabolism with little (<3%) unchanged drug recovered in the urine and feces. 57% of the oral dose is excreted in the feces and 27% is excreted into the urine. The primary metabolite in urine and feces was the carboxylic acid metabolite (73%). The amount of glucuronide in the urine is low.
Half lifeThe effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.
Clearance

Apparent clearance (CL/F), single oral 200 mg dose, healthy subjects = 27.7 L/hr.

ToxicitySymptoms of overdose include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Celecoxib Action PathwayDrug actionSMP00096
Celecoxib Metabolism PathwayDrug metabolismSMP00644
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712
rs1057910 CYP2C9*1C AllelePoor drug metabolizer, lower dose requirements12893985
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9713
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.9287
P-glycoprotein inhibitor INon-inhibitor0.8619
P-glycoprotein inhibitor IINon-inhibitor0.792
Renal organic cation transporterNon-inhibitor0.8582
CYP450 2C9 substrateNon-substrate0.6237
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5751
CYP450 1A2 substrateInhibitor0.7805
CYP450 2C9 inhibitorInhibitor0.6172
CYP450 2D6 inhibitorNon-inhibitor0.8594
CYP450 2C19 inhibitorInhibitor0.7169
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7392
Ames testNon AMES toxic0.7185
CarcinogenicityNon-carcinogens0.7905
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3719 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9856
hERG inhibition (predictor II)Non-inhibitor0.8419
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg/1
Capsuleoral100 mg
Capsuleoral200 mg/1
Capsuleoral200 mg
Capsuleoral400 mg/1
Capsuleoral50 mg/1
Hard capsulesOral use200 mg
Hard capsulesOral use400 mg
Prices
Unit descriptionCostUnit
Celebrex 400 mg capsule6.78USD capsule
Celebrex 200 mg capsule4.52USD capsule
Celebrex 100 mg capsule2.75USD capsule
Celebrex 50 mg capsule1.26USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2177576 No1999-10-262014-11-14Canada
CA2267186 No2002-05-142017-10-14Canada
US5466823 No1993-11-302013-11-30Us
US5972986 No1998-04-142018-04-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158 °CPhysProp
water solubilityVery low water solubility (3.3 mg/L)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00503 mg/mLALOGPS
logP3.99ALOGPS
logP4.01ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)10.7ChemAxon
pKa (Strongest Basic)-0.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.98 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity92.23 m3·mol-1ChemAxon
Polarizability35.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5466823
General References
  1. Malhotra S, Shafiq N, Pandhi P: COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed. 2004 Mar 23;6(1):6. [PubMed:15208519 ]
  2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. [PubMed:10979111 ]
  3. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15. [PubMed:15713944 ]
  4. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford). 2007 Jan;46(1):135-40. Epub 2006 Jun 15. [PubMed:16777855 ]
  5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84. [PubMed:16943400 ]
  6. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002 Oct;54(4):423-9. [PubMed:12392591 ]
External Links
ATC CodesM01AH01L01XX33
AHFS Codes
  • 28:08.04.08
PDB EntriesNot Available
FDA labelDownload (174 KB)
MSDSDownload (102 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Celecoxib.
AbciximabCelecoxib may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Celecoxib can be decreased when combined with Abiraterone.
AcebutololCelecoxib may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Aceclofenac.
AcenocoumarolCelecoxib may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Celecoxib.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Celecoxib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Celecoxib.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Celecoxib.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Celecoxib.
Alendronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.
AliskirenCelecoxib may decrease the antihypertensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Celecoxib.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Celecoxib.
AlprenololCelecoxib may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Celecoxib.
AmikacinCelecoxib may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideCelecoxib may decrease the antihypertensive activities of Amiloride.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Celecoxib.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Celecoxib.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Celecoxib.
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Celecoxib.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Celecoxib.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Celecoxib.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Celecoxib.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Celecoxib.
AncrodCelecoxib may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Antipyrine.
Antithrombin III humanCelecoxib may increase the anticoagulant activities of Antithrombin III human.
ApixabanCelecoxib may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Celecoxib is combined with Apremilast.
AprepitantThe serum concentration of Celecoxib can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Celecoxib.
ArdeparinCelecoxib may increase the anticoagulant activities of Ardeparin.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Celecoxib.
ArgatrobanCelecoxib may increase the anticoagulant activities of Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.
ArotinololCelecoxib may decrease the antihypertensive activities of Arotinolol.
ArtemetherThe metabolism of Artemether can be decreased when combined with Celecoxib.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Celecoxib.
AtazanavirThe metabolism of Celecoxib can be decreased when combined with Atazanavir.
AtenololCelecoxib may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Celecoxib can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Celecoxib.
AzapropazoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Celecoxib.
BalsalazideCelecoxib may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Celecoxib.
BecaplerminCelecoxib may increase the anticoagulant activities of Becaplermin.
BefunololCelecoxib may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Celecoxib.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Celecoxib.
BenoxaprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Benoxaprofen.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Celecoxib.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Celecoxib.
BepridilThe metabolism of Bepridil can be decreased when combined with Celecoxib.
BeraprostThe metabolism of Beraprost can be decreased when combined with Celecoxib.
BetaxololCelecoxib may decrease the antihypertensive activities of Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Celecoxib.
BevantololCelecoxib may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Celecoxib can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Celecoxib.
BisoprololCelecoxib may decrease the antihypertensive activities of Bisoprolol.
BivalirudinCelecoxib may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Celecoxib can be decreased when combined with Boceprevir.
BopindololCelecoxib may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Celecoxib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Celecoxib can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Celecoxib.
BromfenacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Bromfenac.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Celecoxib.
BufuralolCelecoxib may decrease the antihypertensive activities of Bufuralol.
BumetanideCelecoxib may decrease the diuretic activities of Bumetanide.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Celecoxib.
BupranololCelecoxib may decrease the antihypertensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Celecoxib.
BupropionThe metabolism of Bupropion can be decreased when combined with Celecoxib.
BuspironeThe metabolism of Buspirone can be decreased when combined with Celecoxib.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Celecoxib.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Celecoxib.
CaffeineThe metabolism of Caffeine can be decreased when combined with Celecoxib.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Celecoxib.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Celecoxib.
CapecitabineThe metabolism of Celecoxib can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Celecoxib.
CaptoprilThe metabolism of Captopril can be decreased when combined with Celecoxib.
CarbamazepineThe metabolism of Celecoxib can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Celecoxib.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Celecoxib.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Celecoxib.
CarprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Carprofen.
CarteololCelecoxib may decrease the antihypertensive activities of Carteolol.
CarvedilolCelecoxib may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Castanospermine.
CeliprololCelecoxib may decrease the antihypertensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Celecoxib can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Celecoxib.
CertoparinCelecoxib may increase the anticoagulant activities of Certoparin.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Celecoxib.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Celecoxib.
ChloroquineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Celecoxib.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Celecoxib.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Celecoxib.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Celecoxib.
CholecalciferolThe metabolism of Celecoxib can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Celecoxib.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Celecoxib.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Celecoxib.
CisaprideThe metabolism of Cisapride can be decreased when combined with Celecoxib.
CitalopramThe metabolism of Citalopram can be decreased when combined with Celecoxib.
Citric AcidCelecoxib may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe metabolism of Celecoxib can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Celecoxib can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Celecoxib.
ClodronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clodronate.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Celecoxib.
ClonidineThe metabolism of Clonidine can be decreased when combined with Celecoxib.
ClonixinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Celecoxib.
ClotrimazoleThe metabolism of Celecoxib can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Celecoxib.
CobicistatThe metabolism of Celecoxib can be decreased when combined with Cobicistat.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Celecoxib.
ColesevelamColesevelam can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Celecoxib can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Celecoxib can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Celecoxib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Celecoxib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Celecoxib.
CyclosporineCelecoxib may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Celecoxib can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Celecoxib is combined with D-Limonene.
Dabigatran etexilateCelecoxib may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Celecoxib.
DalteparinCelecoxib may increase the anticoagulant activities of Dalteparin.
DanaparoidCelecoxib may increase the anticoagulant activities of Danaparoid.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Celecoxib.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Celecoxib.
DapsoneThe metabolism of Dapsone can be decreased when combined with Celecoxib.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Celecoxib.
DarunavirThe metabolism of Celecoxib can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Celecoxib.
DasatinibThe serum concentration of Celecoxib can be increased when it is combined with Dasatinib.
DaunorubicinCelecoxib may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Celecoxib.
DeferasiroxThe serum concentration of Celecoxib can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Celecoxib is combined with Deferasirox.
DelavirdineThe metabolism of Celecoxib can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Celecoxib.
DesirudinCelecoxib may increase the anticoagulant activities of Desirudin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Celecoxib.
DesmopressinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.
DexamethasoneThe serum concentration of Celecoxib can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Celecoxib.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Celecoxib.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Celecoxib.
DextranCelecoxib may increase the anticoagulant activities of Dextran.
Dextran 40Celecoxib may increase the anticoagulant activities of Dextran 40.
Dextran 70Celecoxib may increase the anticoagulant activities of Dextran 70.
Dextran 75Celecoxib may increase the anticoagulant activities of Dextran 75.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Celecoxib.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Celecoxib.
DiazepamThe metabolism of Diazepam can be decreased when combined with Celecoxib.
DiclofenacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Diclofenac.
DicoumarolCelecoxib may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Celecoxib is combined with Diflunisal.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Celecoxib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Celecoxib.
DigoxinDigoxin may decrease the cardiotoxic activities of Celecoxib.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Celecoxib.
DihydroergotamineThe metabolism of Celecoxib can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinCelecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Celecoxib can be decreased when combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Celecoxib.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Celecoxib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Celecoxib.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Celecoxib.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Celecoxib.
DonepezilThe metabolism of Donepezil can be decreased when combined with Celecoxib.
DopamineThe metabolism of Dopamine can be decreased when combined with Celecoxib.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Celecoxib.
DoxepinThe metabolism of Doxepin can be decreased when combined with Celecoxib.
DoxorubicinCelecoxib may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Celecoxib can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Celecoxib can be decreased when combined with Dronedarone.
DrospirenoneCelecoxib may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Droxicam.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Celecoxib.
Edetic AcidCelecoxib may increase the anticoagulant activities of Edetic Acid.
EdoxabanCelecoxib may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Celecoxib can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Celecoxib.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Celecoxib.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Celecoxib.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Celecoxib.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Celecoxib.
EncainideThe metabolism of Encainide can be decreased when combined with Celecoxib.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Celecoxib.
EnoxaparinCelecoxib may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Celecoxib can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Celecoxib.
EpinastineThe metabolism of Epinastine can be decreased when combined with Celecoxib.
EpirizoleThe risk or severity of adverse effects can be increased when Celecoxib is combined with Epirizole.
EpirubicinCelecoxib may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneCelecoxib may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Celecoxib.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Celecoxib.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Celecoxib.
ErythromycinThe metabolism of Celecoxib can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Celecoxib.
Eslicarbazepine acetateThe serum concentration of Celecoxib can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Celecoxib.
EsmololCelecoxib may decrease the antihypertensive activities of Esmolol.
EstradiolThe metabolism of Estradiol can be decreased when combined with Celecoxib.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Celecoxib.
Etacrynic acidCelecoxib may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Celecoxib.
Ethyl biscoumacetateCelecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Celecoxib.
Etidronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etoricoxib.
EtravirineThe serum concentration of Celecoxib can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Celecoxib is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fenoprofen.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Celecoxib.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Celecoxib.
FlecainideThe metabolism of Flecainide can be decreased when combined with Celecoxib.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Celecoxib.
FloxuridineThe metabolism of Celecoxib can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Celecoxib can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Celecoxib.
FlunixinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flunixin.
FluorouracilThe metabolism of Celecoxib can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Celecoxib.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Celecoxib.
FlurbiprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flurbiprofen.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Celecoxib.
FluvoxamineThe metabolism of Celecoxib can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Celecoxib.
Fondaparinux sodiumCelecoxib may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Celecoxib.
FormoterolThe metabolism of Formoterol can be decreased when combined with Celecoxib.
FosamprenavirThe metabolism of Celecoxib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Celecoxib can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Celecoxib.
FosphenytoinThe metabolism of Celecoxib can be increased when combined with Fosphenytoin.
FramycetinCelecoxib may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideCelecoxib may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Celecoxib can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Celecoxib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Celecoxib.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Celecoxib.
GemfibrozilThe metabolism of Celecoxib can be decreased when combined with Gemfibrozil.
GentamicinCelecoxib may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GranisetronThe metabolism of Granisetron can be decreased when combined with Celecoxib.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Celecoxib.
HaloperidolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Celecoxib.
HeparinCelecoxib may increase the anticoagulant activities of Heparin.
HirulogCelecoxib may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Celecoxib is combined with HMPL-004.
HydralazineCelecoxib may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Celecoxib.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Celecoxib.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Celecoxib.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Celecoxib.
Hygromycin BCelecoxib may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibandronate.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Celecoxib.
IbuprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Celecoxib is combined with Icatibant.
IdarubicinCelecoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Celecoxib can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Celecoxib.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Celecoxib.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Celecoxib.
ImatinibThe metabolism of Celecoxib can be decreased when combined with Imatinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Celecoxib.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib.
IndenololCelecoxib may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Celecoxib can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.
IndoprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Indoprofen.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Celecoxib.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Celecoxib.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Celecoxib.
IsavuconazoniumThe metabolism of Celecoxib can be decreased when combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Isoxicam.
IsradipineThe metabolism of Celecoxib can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Celecoxib can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Celecoxib can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Celecoxib.
KanamycinCelecoxib may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Kebuzone.
KetamineThe metabolism of Ketamine can be decreased when combined with Celecoxib.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Celecoxib.
KetoconazoleThe metabolism of Celecoxib can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Celecoxib.
LabetalolCelecoxib may decrease the antihypertensive activities of Labetalol.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Celecoxib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Celecoxib.
LeflunomideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Leflunomide.
LepirudinCelecoxib may increase the anticoagulant activities of Lepirudin.
LevobunololCelecoxib may decrease the antihypertensive activities of Levobunolol.
LevodopaThe metabolism of Levodopa can be decreased when combined with Celecoxib.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Celecoxib.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Celecoxib.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Celecoxib.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Celecoxib.
LisurideThe metabolism of Lisuride can be decreased when combined with Celecoxib.
LithiumThe serum concentration of Lithium can be increased when it is combined with Celecoxib.
LomustineThe metabolism of Lomustine can be decreased when combined with Celecoxib.
LoperamideThe metabolism of Loperamide can be decreased when combined with Celecoxib.
LopinavirThe metabolism of Celecoxib can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Celecoxib.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Celecoxib.
LornoxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Celecoxib.
LosartanThe metabolism of Losartan can be decreased when combined with Celecoxib.
LovastatinThe metabolism of Celecoxib can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Celecoxib.
LuliconazoleThe serum concentration of Celecoxib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Celecoxib can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Magnesium salicylate.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Celecoxib.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Celecoxib.
MecamylamineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mecamylamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Meloxicam.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Celecoxib.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Celecoxib.
MesalazineCelecoxib may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Celecoxib.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Celecoxib.
MetamizoleThe risk or severity of adverse effects can be increased when Celecoxib is combined with Metamizole.
MethadoneThe metabolism of Methadone can be decreased when combined with Celecoxib.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Celecoxib.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Celecoxib.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Celecoxib.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Celecoxib.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Celecoxib.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Celecoxib.
MetipranololCelecoxib may decrease the antihypertensive activities of Metipranolol.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Celecoxib.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib.
MetoprololCelecoxib may decrease the antihypertensive activities of Metoprolol.
MetrizamideCelecoxib may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Celecoxib.
MianserinThe metabolism of Mianserin can be decreased when combined with Celecoxib.
MifepristoneThe metabolism of Celecoxib can be decreased when combined with Mifepristone.
MinaprineThe metabolism of Minaprine can be decreased when combined with Celecoxib.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Celecoxib.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Celecoxib.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Celecoxib.
MitotaneThe serum concentration of Celecoxib can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Celecoxib.
ModafinilThe serum concentration of Celecoxib can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Celecoxib.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Celecoxib.
MorphineThe metabolism of Morphine can be decreased when combined with Celecoxib.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Celecoxib.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Celecoxib.
NadololCelecoxib may decrease the antihypertensive activities of Nadolol.
NadroparinCelecoxib may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Celecoxib can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Naftifine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Celecoxib.
NaproxenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Naproxen.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Celecoxib.
NCX 4016The risk or severity of adverse effects can be increased when Celecoxib is combined with NCX 4016.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Celecoxib.
NefazodoneThe metabolism of Celecoxib can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Celecoxib can be decreased when combined with Nelfinavir.
NeomycinCelecoxib may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nepafenac.
NetilmicinCelecoxib may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Celecoxib can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Celecoxib.
NevirapineThe metabolism of Celecoxib can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Celecoxib.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Celecoxib.
NicotineThe metabolism of Nicotine can be decreased when combined with Celecoxib.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Celecoxib.
Niflumic AcidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Niflumic Acid.
NilotinibThe metabolism of Celecoxib can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nimesulide.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Celecoxib.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Celecoxib.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Celecoxib.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Celecoxib.
OlaparibThe metabolism of Celecoxib can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Celecoxib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Celecoxib.
OlopatadineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Olopatadine.
OlsalazineCelecoxib may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Celecoxib.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Celecoxib.
OmeprazoleThe metabolism of Celecoxib can be decreased when combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Celecoxib.
OrgoteinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Orgotein.
OsimertinibThe serum concentration of Celecoxib can be increased when it is combined with Osimertinib.
OtamixabanCelecoxib may increase the anticoagulant activities of Otamixaban.
OuabainOuabain may decrease the cardiotoxic activities of Celecoxib.
OxaprozinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oxaprozin.
OxprenololCelecoxib may decrease the antihypertensive activities of Oxprenolol.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Celecoxib.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Celecoxib.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oxyphenbutazone.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Celecoxib.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Celecoxib.
PalbociclibThe serum concentration of Celecoxib can be increased when it is combined with Palbociclib.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Celecoxib.
PamidronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pamidronate.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Celecoxib.
ParecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Parecoxib.
ParomomycinCelecoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Celecoxib.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Celecoxib.
PenbutololCelecoxib may decrease the antihypertensive activities of Penbutolol.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Celecoxib.
PentobarbitalThe metabolism of Celecoxib can be increased when combined with Pentobarbital.
Pentosan PolysulfateCelecoxib may increase the anticoagulant activities of Pentosan Polysulfate.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Celecoxib.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Celecoxib.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Celecoxib.
PethidineThe metabolism of Pethidine can be decreased when combined with Celecoxib.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Celecoxib.
PhenforminThe metabolism of Phenformin can be decreased when combined with Celecoxib.
PhenindioneCelecoxib may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Celecoxib can be increased when combined with Phenobarbital.
PhenprocoumonCelecoxib may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Phenylbutazone.
PhenytoinThe metabolism of Celecoxib can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Celecoxib.
PindololCelecoxib may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Celecoxib.
PiperazineThe metabolism of Piperazine can be decreased when combined with Celecoxib.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Celecoxib.
PiretanideCelecoxib may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Piroxicam.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Celecoxib.
PlicamycinCelecoxib may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Celecoxib.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Celecoxib.
PosaconazoleThe metabolism of Celecoxib can be decreased when combined with Posaconazole.
PractololCelecoxib may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Celecoxib.
PrilocaineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prilocaine.
PrimidoneThe metabolism of Celecoxib can be increased when combined with Primidone.
ProbenecidThe serum concentration of Celecoxib can be increased when it is combined with Probenecid.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Celecoxib.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Celecoxib.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Celecoxib.
PromethazineThe metabolism of Promethazine can be decreased when combined with Celecoxib.
PropacetamolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Propacetamol.
PropafenoneThe serum concentration of Celecoxib can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Celecoxib.
PropofolThe metabolism of Propofol can be decreased when combined with Celecoxib.
PropranololCelecoxib may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Celecoxib.
Protein CCelecoxib may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeCelecoxib may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Celecoxib.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Celecoxib.
PTC299The risk or severity of adverse effects can be increased when Celecoxib is combined with PTC299.
PuromycinCelecoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Celecoxib can be decreased when combined with Pyrimethamine.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Celecoxib.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Celecoxib.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Celecoxib.
QuinidineThe metabolism of Quinidine can be decreased when combined with Celecoxib.
QuinineThe metabolism of Quinine can be decreased when combined with Celecoxib.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Celecoxib.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Celecoxib.
RanolazineThe metabolism of Celecoxib can be decreased when combined with Ranolazine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Celecoxib.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Celecoxib.
repinotanThe metabolism of repinotan can be decreased when combined with Celecoxib.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Celecoxib.
ResveratrolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Resveratrol.
ReviparinCelecoxib may increase the anticoagulant activities of Reviparin.
RibostamycinCelecoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Celecoxib can be increased when combined with Rifabutin.
RifampicinThe metabolism of Celecoxib can be increased when combined with Rifampicin.
RifapentineThe metabolism of Celecoxib can be increased when combined with Rifapentine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Celecoxib.
RisedronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Risedronate.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Celecoxib.
RitonavirThe metabolism of Celecoxib can be decreased when combined with Ritonavir.
RivaroxabanCelecoxib may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Rofecoxib.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Celecoxib.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Celecoxib.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Celecoxib.
SalicylamideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Celecoxib.
SaquinavirThe metabolism of Celecoxib can be decreased when combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Celecoxib.
SecobarbitalThe metabolism of Celecoxib can be increased when combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Celecoxib.
SelexipagThe metabolism of Selexipag can be decreased when combined with Celecoxib.
SeratrodastThe risk or severity of adverse effects can be increased when Celecoxib is combined with Seratrodast.
SertindoleThe metabolism of Sertindole can be decreased when combined with Celecoxib.
SertralineThe metabolism of Sertraline can be decreased when combined with Celecoxib.
SildenafilThe metabolism of Celecoxib can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Celecoxib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Celecoxib can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Celecoxib.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Celecoxib.
Sodium NitriteThe risk or severity of adverse effects can be increased when Celecoxib is combined with Sodium Nitrite.
SorafenibThe metabolism of Celecoxib can be decreased when combined with Sorafenib.
SotalolCelecoxib may decrease the antihypertensive activities of Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Celecoxib.
SpectinomycinCelecoxib may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Celecoxib.
SpironolactoneCelecoxib may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Celecoxib is combined with SRT501.
St. John's WortThe serum concentration of Celecoxib can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe serum concentration of Celecoxib can be increased when it is combined with Stiripentol.
StreptomycinCelecoxib may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinCelecoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Celecoxib can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Celecoxib can be decreased when combined with Sulfamethoxazole.
SulfasalazineCelecoxib may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Celecoxib.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Celecoxib.
SulfisoxazoleThe metabolism of Celecoxib can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Sulindac.
SulodexideCelecoxib may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Suprofen.
TacrolimusCelecoxib may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Celecoxib.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Celecoxib.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Celecoxib.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Celecoxib.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Celecoxib.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Celecoxib.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Technetium Tc-99m Medronate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Celecoxib.
TelaprevirThe metabolism of Celecoxib can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Celecoxib can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Celecoxib.
TemazepamThe metabolism of Temazepam can be decreased when combined with Celecoxib.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Celecoxib.
TenofovirThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Celecoxib.
TepoxalinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tepoxalin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Celecoxib.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Celecoxib.
TeriflunomideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Celecoxib.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Celecoxib.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Celecoxib.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Celecoxib.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Celecoxib.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Celecoxib can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Celecoxib can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tiludronate.
TimololCelecoxib may decrease the antihypertensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Celecoxib.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Celecoxib.
TobramycinCelecoxib may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Celecoxib can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Celecoxib can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tolmetin.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Celecoxib.
TorasemideThe metabolism of Torasemide can be decreased when combined with Celecoxib.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Celecoxib.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Celecoxib.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Celecoxib.
TranilastThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tranilast.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Celecoxib.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Celecoxib.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Celecoxib.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Celecoxib.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Celecoxib.
TriamtereneCelecoxib may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Celecoxib.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Celecoxib.
TrimethoprimThe metabolism of Celecoxib can be decreased when combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Celecoxib.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Trisalicylate-choline.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Celecoxib.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Celecoxib.
ValdecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Valdecoxib.
Valproic AcidThe metabolism of Celecoxib can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Celecoxib.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Celecoxib.
VenlafaxineThe metabolism of Celecoxib can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Celecoxib can be decreased when combined with Verapamil.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Celecoxib.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Celecoxib.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Celecoxib.
VoriconazoleThe metabolism of Celecoxib can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Celecoxib.
WarfarinCelecoxib may increase the anticoagulant activities of Warfarin.
XimelagatranCelecoxib may increase the anticoagulant activities of Ximelagatran.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Celecoxib.
ZafirlukastThe metabolism of Celecoxib can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Celecoxib.
ZaltoprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zaltoprofen.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Celecoxib.
ZileutonThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zileuton.
ZiprasidoneThe metabolism of Celecoxib can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zoledronic acid.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Celecoxib.
ZomepiracThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zomepirac.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Celecoxib.
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Celecoxib.
Food Interactions
  • Take without regard to meals.
  • Taking this product with a high-fat meal will delay the Cmax, but total absorption will be increased by 10 to 20%.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002 Jun;122(7):1913-23. [PubMed:12055598 ]
  2. Scheiman JM: Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 2002;69 Suppl 1:SI40-6. [PubMed:12086292 ]
  3. Reddy BS, Rao CV: Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol. 2002;21(2):155-64. [PubMed:12086402 ]
  4. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537-44. [PubMed:12093311 ]
  5. Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett. 2002 Oct 8;184(1):7-12. [PubMed:12104042 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), ser...
Gene Name:
PDPK1
Uniprot ID:
O15530
Molecular Weight:
63151.305 Da
References
  1. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004 Feb 15;64(4):1444-51. [PubMed:14973075 ]
  2. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. [PubMed:15205346 ]
  3. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP: Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005 Oct 15;391(Pt 2):441-8. [PubMed:16060857 ]
  4. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P: A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg. 2006 Feb;10(2):207-14. [PubMed:16455452 ]
  5. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3. [PubMed:16887935 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar;38(3):225-42. [PubMed:10749518 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
  6. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K: Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003 Aug;74(2):130-7. [PubMed:12891223 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23